REhabilitation and COVid Recovery (RECOVR) Study

REhabilitation and COVid Recovery (RECOVR) Study

The COVID-19 pandemic has been an unprecedented event in our lifetime. Care for persons stricken with the SARS-CoV-2 virus has occurred across the healthcare system from primary care to acute care to post-acute and long-term care. Since March 30, 2020, approximately 400 people have received inpatient rehabilitation for COVID-19 illness across the Spaulding Rehabilitation Network. In light of this novel virus and uncertainty around the potential long-term impacts on patients’ cognitive, physical, social, and emotional function, the SRN Research Faculty initiated the RECOVR Study” in April 2020.

The aims of the RECOVR study are to:

  1. Determine if there are distinct post-acute COVID-19 endophenotypes (primary aim)
  2. Identify different trajectories of recovery from COVID-19 within the first 12 months post-onset (secondary aim).

Participation in the RECOVR study involves completion of questionnaires, a test of mental abilities, a blood draw, and a short physical function test during the inpatient admission at Spaulding. Participants are then contacted via telephone at 3-, 6-, and 12-months following their COVID-19 diagnosis to complete questionnaires and a test of mental abilities. In addition, participants are invited to participate in an optional portion of the study in which they are provided with a wearable sensor that looks like a wristwatch. The sensor allows us to monitor participants’ health.

Since June 2020, 135 participants have enrolled in the study, 55 of whom have completed their 12-month follow-up.

Speakers for the Harvard Medical Virtual Grand Rounds event on May 6th, 2021 collectively examined the post-acute sequelae of SARS CoV-2 (PASC, or Long covid). Dr. Joseph Giacino presented preliminary findings from the RECOVR study and reviewed the results of ongoing data analysis on the functional impairment, outcome, and recovery of patients 6 months after hospitalization for severe COVID illness.

Principal Investigator: Joseph T. Giacino, PhD

Study Contact: Michael Bergin, PhD (